Aptinyx Inc (NASDAQ:APTX) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $26.00 and last traded at $24.87, with a volume of 6987 shares changing hands. The stock had previously closed at $24.12.

Several research firms have issued reports on APTX. Leerink Swann began coverage on shares of Aptinyx in a research report on Monday, July 16th. They issued an “outperform” rating and a $35.00 price objective for the company. Cowen assumed coverage on shares of Aptinyx in a research report on Monday, July 16th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Aptinyx in a research report on Monday, July 16th. They issued an “overweight” rating and a $30.00 price target for the company. Finally, BMO Capital Markets assumed coverage on shares of Aptinyx in a research report on Monday, July 16th. They issued an “outperform” rating and a $32.00 price target for the company.

Aptinyx (NASDAQ:APTX) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($1.83) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($1.35). The firm had revenue of $2.13 million for the quarter, compared to analysts’ expectations of $2.10 million. sell-side analysts forecast that Aptinyx Inc will post -2.12 EPS for the current year.

In other Aptinyx news, CEO Norbert G. Riedel purchased 2,400 shares of the stock in a transaction dated Monday, June 25th. The stock was purchased at an average price of $16.00 per share, with a total value of $38,400.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Adam Koppel purchased 400,000 shares of the stock in a transaction dated Monday, June 25th. The stock was acquired at an average cost of $16.00 per share, with a total value of $6,400,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 566,900 shares of company stock valued at $9,070,400 in the last ninety days.

Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Hong Kong Ltd purchased a new stake in shares of Aptinyx in the 2nd quarter worth approximately $134,000. Birchview Capital LP bought a new position in shares of Aptinyx during the 2nd quarter worth approximately $242,000. TD Asset Management Inc. bought a new position in shares of Aptinyx during the 2nd quarter worth approximately $253,000. Mutual of America Capital Management LLC bought a new position in shares of Aptinyx during the 2nd quarter worth approximately $457,000. Finally, Cowen Inc. bought a new position in shares of Aptinyx during the 2nd quarter worth approximately $546,000. 60.05% of the stock is owned by hedge funds and other institutional investors.

Aptinyx Company Profile (NASDAQ:APTX)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Article: Google Finance

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.